Laura Pettit

Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial

Hisham Mehanna, Max Robinson, A. Hartley et al. · The Lancet · 2018 · 1K citations · Full text

Medicine, Oncology, Radiation Oncology +12

6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial

Helena Earl, Louise Hiller, Anne-Laure Vallier et al. · The Lancet · 2019 · 283 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Dysphagia-optimised intensity-modulated radiotherapy versus standard intensity-modulated radiotherapy in patients with head and neck cancer (DARS): a phase 3, multicentre, randomised, controlled trial

Christopher M. Nutting, Laura Finneran, Justin Roe et al. · The Lancet Oncology · 2023 · 105 citations · Full text

Medicine, Oncology, Radiation Oncology +17

Quality of life after breast-conserving therapy and adjuvant radiotherapy for non-low-risk ductal carcinoma in situ (BIG 3-07/TROG 07.01): 2-year results of a randomised, controlled, phase 3 trial

Madeleine King, Emma Link, Timothy J. Whelan et al. · The Lancet Oncology · 2020 · 52 citations

Medicine, Oncology, Radiation Oncology +14

Effect of Celecoxib vs Placebo as Adjuvant Therapy on Disease-Free Survival Among Patients With Breast Cancer

R. Charles Coombes, Holly Tovey, Lucy Kilburn et al. · JAMA Oncology · 2021 · 47 citations · Full text

Medicine, Oncology, Pharmacology +15